Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.023
Buy
RSI(14)
53.682
Neutral
STOCH(KDJ)(9,3,3)
61.403
Neutral
ATR(14)
0.201
Low Volatility
CCI(14)
62.165
Neutral
Williams %R
39.228
Buy
TRIX(12,20)
-0.010
Sell
StochRSI(14)
68.323
Sell
Search
Rezolute Inc
RZLTAdd to Watchlist
3.340USD
-0.060-1.76%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
321.62MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Rezolute Inc
Currency: USD Updated: 2026-05-15Key Insights
Rezolute Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.62.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rezolute Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rezolute Inc Highlights
StrengthsRisks
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -4.10, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.63M shares, decreasing 0.59% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 8.07K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.29.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
7.625
Target Price
+124.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Rezolute Inc is 5.45, ranking 355 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.45
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Rezolute Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Rezolute Inc is 6.36, ranking 278 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.10, which is -83.64% below the recent high of -0.67 and -185.44% above the recent low of -11.71.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 86/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Rezolute Inc is 7.80, ranking 274 out of 382 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 20.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
7.625
Target Price
+124.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Rezolute Inc
RZLT
10
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Rezolute Inc is 8.97, ranking 42 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.60 and the support level at 3.03, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.308
Buy
MA10
3.257
Buy
MA20
3.238
Buy
MA50
3.147
Buy
MA100
3.061
Buy
MA200
5.516
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Rezolute Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 105.15%, representing a quarter-over-quarter decrease of 4.87%. The largest institutional shareholder is James Simons, holding a total of 157.71K shares, representing 0.16% of shares outstanding, with 62.79% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Rezolute Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.69
VaR
+7.86%
240-Day Maximum Drawdown
+87.20%
240-Day Volatility
+242.03%
Return
Best Daily Return
60 days
+18.22%
120 days
+28.57%
5 years
+52.41%
Worst Daily Return
60 days
-14.07%
120 days
-87.20%
5 years
-87.20%
Sharpe Ratio
60 days
+0.02
120 days
+0.44
5 years
+0.38
Risk Assessment
Maximum Drawdown
240 days
+87.20%
3 years
+87.20%
5 years
+93.50%
Return-to-Drawdown Ratio
240 days
-0.24
3 years
+0.25
5 years
-0.15
Skewness
240 days
-5.08
3 years
-3.18
5 years
-1.58
Volatility
Realised Volatility
240 days
+242.03%
5 years
+146.55%
Standardised True Range
240 days
+12.69%
5 years
+9.21%
Downside Risk-Adjusted Return
120 days
+43.37%
240 days
+43.37%
Maximum Daily Upside Volatility
60 days
+86.53%
Maximum Daily Downside Volatility
60 days
+53.80%
Liquidity
Average Turnover Rate
60 days
+2.48%
120 days
+5.28%
5 years
--
Turnover Deviation
20 days
-29.14%
60 days
+11.26%
120 days
+136.82%
Peer Comparison
Biotechnology & Medical Research
Rezolute Inc
RZLT
6.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
